We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Diaceutics Plc | DXRX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 4.50 | 3.77% | 124.00 | 09:19:50 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 122.50 | 122.50 | 124.00 | 124.00 | 119.50 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 06/9/2024 07:44 by mginvestor melody, no reduction, have a listen to this interview with Peter, who was the previous CEO and still a significant holder.A friend and fellow investor reminded me of this recently and said "Just listened to this again from March 2023 so nearly 18 months ago. Peter Keeling talks of 180 lab network, now around 1000 and really pleased that Signal was as good as 3 or 4 days, now daily in the US. Incredible progress in a short period of time." |
Posted at 05/9/2024 15:41 by melody9999 Thanks MG ...reduction in labs then from 2.5 to 1K?Obviously the platform is the key attribute - I'd like to gain some more insight into the revenue modeland the moat....what is it that is most attractive to customers. I'll look in at Investor Meet. |
Posted at 05/9/2024 10:01 by melody9999 Smithie - I've just done a little digging here too.DXRX is providing a precision medicine platform - The Diagnostics Network (TDN). It gathers info from over 2500 labs - allowing access to pharma / biotech to obtain data and to collaborate. What is precision medicine? Looked up and defined as treatment using information about a person's genes, proteins, environment, and lifestyle. I doubt TDN is patient based - from the schematic it looks disease / research based Scroll down this page for a useful schematic: Have a look at this video Any current investors ... please correct me if my understanding is wrong. |
Posted at 15/3/2024 06:47 by hastings Wisecat2, it is wrong to say you can't look at the research unless you pay.Like many other quoted companies the brokers covering DXRX just don't make the info readily available to private investors.It isn't something I agree with as I believe in a level playing field, but it is unfortunately still quite common. I'm fortunate enough to have seen three of the notes including the most recent initiation from Panmure, all of which make for good reading. |
Posted at 15/3/2024 06:38 by wisecat2 Martin follows Filtronic. Have a look at the quality website and then look at DXRX and how cheap and out of date it is. Not good. Look at research no you cant unless you paynot a great way to attract new shareholders. Saying that it is an interesting company but needs to help potential investors, there a lot of cheap quality companies out there |
Posted at 15/5/2023 15:00 by melloteam Just to let shareholders and prospective investors know that Diaceutics will be presenting on the MelloMonday webinar at 5pm today. The programme for the evening is as follows: 5.00 pm Mello welcome followed by a Question & Answer session from Sosandar 5.30 pm Company presentation from Diaceutics 6.10 pm Company presentation from WiseAlpha 6.50 pm Mello BASH with Damian Cannon & Kevin Taylor featuring Ten Entertainment Group (TEG) and Barratt Developments (BDEV) There will be over 500 investors attending and these are very popular shows with company presentations, fund manager and investor interviews, and panel sessions. Tickets for today's event are FREE so make sure you tune in and take advantage! |
Posted at 05/4/2023 11:17 by chrisdgb Finals week after next should give next focus for investors....... |
Posted at 27/7/2022 18:17 by hedgehog 100 "DIACEUTICS TO BECOME FOURTH NORTHERN IRISH COMPANY LISTED ON LONDON STOCK EXCHANGERONAN LEONARD MARCH 18, 2019 Diaceutics plc, a revenue-generating, and profitable diagnostics data analytics and implementation services company which services the global pharmaceutical industry, today announces that it is seeking a listing on the AIM Market of the London Stock Exchange. This will make Diaceutics the fourth Northern Irish company currently listed on the London Stock Exchange. The company is expected to have a market capitalisation on admission of approximately £53M. ..." Rockpool Acquisitions (ROC) is a main-listed cash shell, which may be of interest to investors seeking other Northern Ireland investments to DXRX:- "A listed acquisition vehicle seeking opportunities in Northern Ireland. Northern Ireland has a good availability of high quality, often internationally-focu With extensive knowledge and experience of the Northern Ireland market, the directors are seeking to identify and acquire a highly ambitious, Northern Ireland-based company that is focused on significant growth, and provide it with that access, helping that company meet its aspirations and full potential. Target companies will have a valuation of up to £20m." Rockpool Acquisitions (ROC) 4.75p Market cap. £604K. ROC has about £950K. cash, and extremely low cashburn. ROC's large discount at the moment to its cash, despite this extremely low cashburn, looks like a temporary discrepancy - and one that is gradually being addressed by ROC's share price rise, as the market wakes up to the opportunity. |
Posted at 06/9/2021 22:33 by sharesoc We are hosting a webinar with Diaceutics PLC (DXRX) on the 22nd September, which may be of interest to shareholders or potential investors. Peter Keeling (CEO & Founder) and Philip White (CFO) will provide the latest updates: |
Posted at 20/5/2021 13:54 by melloteam Just to let shareholders and prospective investors know that Diaceutics, ANGLE plc, Inspiration Healthcare Group plc, Polarean Imaging plc and IBT will be presenting at Mello Events’ Healthcare webinar on the 25th May at 5:30pm-9:30pm. The webinar will also include the latest insights and analysis from investment managers, research professionals, analysts and experienced investors. If you are a shareholder and you would like a ticket to the Healthcare event, please use the code SHVIP75 to receive 75% off your ticket. Additionally, on the 24th May, The Property Franchise Group PLC and Samarkand will be presenting at the MELLOMonday webinar event on 24th May at 6pm-9:30pm. There will also be special insights from Michael Taylor (@shiftingshares): Using technical analysis to find trades. There will be over 600 investors attending and these are very popular shows with company presentations, fund manager and investor interviews, and panel sessions including the popular Mello BASH (Buy, Avoid, Sell or Hold). If you purchase a ticket to MELLOMonday, you will automatically get sent a link to the healthcare event! Tickets are still available and if you would like one at half price then enter the code MMTADVFN50. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
